Do FDA-approved Alzheimer’s drugs like Leqembi and Kisunla actually stop disease progression?

No, in clinical trials Leqembi and Kisunla were linked with a small-to-modest slowing of cognitive decline over 18 months. This suggests these treatments may slow, but not stop, the disease.